| |
n = 331
|
|---|
|
Age, years (range)
|
60 (29–87)
|
|
BMI (range)
|
26.8 (17.3–50.7)
|
|
ECOG
| |
|
0
|
219 (66%)
|
|
1
|
108 (33%)
|
|
2
|
4 (1%)
|
|
Laterality
| |
|
Right
|
163 (49%)
|
|
Left
|
168 (51%)
|
|
Histology
| |
|
Invasive ductal
|
283 (85%)
|
|
Invasive lobular
|
13 (4%)
|
|
Mixed
|
5 (2%)
|
|
Other
|
30 (9%)
|
|
Grade
| |
|
1
|
71 (21%)
|
|
2
|
148 (45%)
|
|
3
|
111 (34%)
|
|
Not reported
|
1 (< 1%)
|
|
pT stage
| |
|
T0
|
25 (8%)
|
|
Tis
|
52 (16%)
|
|
T1
|
169 (51%)
|
|
T2
|
63 (19%)
|
|
T3
|
21 (6%)
|
|
Not reported
|
1 (< 1%)
|
|
Nodal status
| |
|
Negative
|
211 (64%)
|
|
Positive
|
87 (26%)
|
|
Not reported
|
33 (10%)
|
|
ER positive
|
271 (82%)
|
|
PR positive
|
255 (77%)
|
|
HER2 positive
|
33 (10%)
|
|
TNBC
|
27 (8%)
|
- BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; PR, progesterone receptor; TNBC, triple negative breast cancer
